Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Augmented Hyper-CVAD in Relapsed/Refractory ALL
NCT00890656Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2003
- Primary completion
- Jan 2011
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Remission. Started Jun 2003; status: completed.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00890656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00890656.